Ralph R. Weichselbaum
Chair
Department of Radiation and Cellular Oncology
The University of Chicago
United States of America
Biography
Dr. Ralph Weichselbaum specializes in the treatment of potentially curative treatment of "oligo" metastasis with radiotherapy. Dr. Weichselbaum's research interests include mechanisms of tumor spread and how radiation therapy and immunotherapy can be used to better treat cancer. He is also studying patterns of gene expression in human tumors that confer resistance to radiotherapy and chemotherapy. Weichselbaum invented a radio-inducible form of gene therapy TNFerade, which is currently in clinical trials. His research has been funded by the National Institutes of Health for more than 35 years. He is also editor of Cancer Medicine, a definitive reference textbook compiled to help oncologists and internists apply scientific principles to clinical practice.
Research Interest
Mechanisms of tumor spread and how radiation therapy and immunotherapy can be used to better treat cancer. He is also studying patterns of gene expression in human tumors that confer resistance to radiotherapy and chemotherapy. Weichselbaum invented a radio-inducible form of gene therapy TNFerade, which is currently in clinical trials.
Publications
-
Rhythmic radiotherapy beats down TGF-β.
-
Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling.
-
TP53 Mutational Status and ROS Effect the Expression of the Survivin-Associated Radio-Adaptive Response.
-
Association between hospital volume and receipt of treatment and survival in patients with glioblastoma.
